EGF and hepatocellular carcinoma: Mechanistically, UCK2 can non-catalytically activate EGFR-AKT pathway by interacting with EGFR to inhibit EGF-induced EGFR ubiquitination and degradation, resulting in enhanced HCC metastasis.